Table 2.
Pre-hospital management and angiographic data.
| Study population n = 407 |
Female n = 64 |
Male n = 343 |
p | |
|---|---|---|---|---|
| Time from symptom onset to hospital arrival (min) | 201 ± 171 | 214 ± 133 | 198 ± 176 | 0.07 |
| Time from admission to treatment | 62 ± 85 | 55 ± 47 | 63 ± 90 | 0.87 |
| Total ischemic time (min) | 263 ± 173 | 264 ± 138 | 263 ± 178 | 0.24 |
| Killip class at admission | ||||
| 1 | 327/371 (88.1%) | 50/59 (84.7%) | 277/312 (88.8%) | |
| >1 | 44/371 (11.9%) | 9/59 (15.3%) | 35/312 (11.2%) | |
| Infarct size | ||||
| Peak CK | 3,986 ± 2,562 | 3,565 ± 2,103 | 4,063 ± 2,633 | 0.3 |
| CK AUC | 65,898 ± 37,298 | 57,674 ± 28,251 | 67,170 ± 38,410 | 0.36 |
| Medication from first medical care to PCI | ||||
| Heparin | 345/406 (85%) | 60/64 (93.8%) | 285/342 (83.3%) | 0.05 |
| GP IIb/IIIa inhibitor | 174/406 (42.9%) | 29/64 (45.3%) | 145/342 (42.4%) | 0.76 |
| Loading dose of P2Y12 inhibitor | 353/406 (86.9%) | 54/64 (84.4%) | 299/342 (87.4%) | 0.64 |
| Aspirin | 375/406 (92.4%) | 57/64 (89.1%) | 318/342 (93%) | 0.30 |
| Morphine | 232/406 (57.1%) | 36/64 (56.2%) | 196/342 (57.3%) | 0.98 |
| Site of LAD occlusion | 0.55 | |||
| Proximal or main | 174 (42.8%) | 30 (46.9%) | 144 (42%) | |
| Medial/distal LAD or diagonal branch | 233 (57.2%) | 34 (53.1%) | 199 (58%) | |
| Area at risk (%) | 36.5 ± 8.4 | 36.9 ± 8.3 | 36.4 ± 8.4 | 0.86 |
| TIMI flow grade before PCI | 0.53 | |||
| 0 | 314/392 (80.1%) | 53/62 (85.5%) | 261/330 (79.1%) | |
| 1 | 50/392 (12.8%) | 5/62 (8.1%) | 45/330 (13.6%) | |
| 2 | 22/392 (5.6%) | 4/62 (6.5%) | 18/330 (5.5%) | |
| 3 | 6/392 (1.5%) | 0/62 (0%) | 6/330 (1.8%) | |
| Thrombus aspiration | 323 (79.4%) | 49 (76.6%) | 274 (79.9%) | 0.66 |
| Direct stenting | 238/392 (60.7%) | 31/62 (50%) | 207/330 (62.7%) | 0.08 |
| Stenting | 357 (87.7%) | 51 (79.7%) | 306 (89.2%) | 0.05 |
| No reflow observed on angiography | 18 (4.4%) | 4 (6.2%) | 14 (4.1%) | 0.50 |
| TIMI flow grade after PCI | 0.38 | |||
| 0 | 4/402 (1%) | 1/64 (1.6%) | 3/338 (0.9%) | |
| 1 | 4/402 (1%) | 1/64 (1.6%) | 3/338 (0.9%) | |
| 2 | 25/402 (6.2%) | 2/64 (3.1%) | 23/338 (6.8%) | |
| 3 | 369/402 (91%) | 60/64 (93.8%) | 309/338 (91.4%) | |
CK, creatinine kinase in UI/L; GP, GlycoProtein.
Data are presented as no./total no. (%). Times are represented as median ± standard deviation. Biological data are represented as absolute numbers. Times are in minutes. Area at risk in %.